BMY
NVDA
Another day, another AI factory
NVIDIA says Bristol Myers Squibb is going to build the “most powerful AI factory in life sciences” using its tech. Which is corporate-speak for: the AI arms race has officially wandered into drug discovery, and the shovels are getting pretty expensive.
For NVIDIA, this is the fun part of the story. The company isn’t just selling chips to hyperscalers and data centers anymore — it’s becoming the default pick for anyone who wants to slap a giant AI brain onto a serious business problem. And if the buyer is a big-name pharma player? Even better. That’s one more proof point that AI demand is broadening, not shrinking.
Why investors should care
This kind of deal matters because it shows NVIDIA’s moat isn’t just about raw GPU horsepower. It’s about being the infrastructure layer everybody else builds on top of. When a company like Bristol Myers Squibb wants to go big on AI, NVIDIA gets to wear the crown, cut the ribbon, and probably sell the picks and shovels too.
The bigger picture
- It expands NVIDIA’s reach deeper into life sciences, a sector where AI could meaningfully speed up research and development.
- It reinforces the idea that NVIDIA’s growth story is still getting new chapters, even as the market hunts for signs the AI boom is cooling.
- And it keeps the “AI factory” buzzword machine humming, which, frankly, is still doing a lot of work on Wall Street.
Big picture: NVIDIA keeps finding new places to plug in its AI empire, and that’s exactly the kind of customer diversification bulls love to see.